At present, drug treatment strategies for advanced HCC are limited, they are mainly based on various molecular targeted therapeutics (8–10), or immune checkpoint inhibitors targeting PD-1/PD-L1 (programmed cell death-1/programmed cell death ligand-1) (11–13). This evidence concerns the gene CD274 and hepatocellular carcinoma.